1 – 10 of 13
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice : Results from the ARTIS programme
(
- Contribution to journal › Article
- 2021
-
Mark
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population : A nationwide Swedish cohort study
(
- Contribution to journal › Article
-
Mark
Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden : From infection severity to impact on care provision
(
- Contribution to journal › Article
- 2019
-
Mark
Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA : Results from the nationwide Swedish register
(
- Contribution to journal › Article
- 2017
-
Mark
Cancer risk in patients with spondyloarthritis treated with TNF inhibitors : A collaborative study from the ARTIS and DANBIO registers
(
- Contribution to journal › Article
- 2016
-
Mark
Ny diagnostik och behandling vid gikt
(
- Contribution to journal › Article
-
Mark
Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis
2016) In Annals of the Rheumatic Diseases(
- Contribution to journal › Article
- 2011
-
Mark
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
(
- Contribution to journal › Article
-
Mark
Ten years with biologics: to whom do data on effectiveness and safety apply?
(
- Contribution to journal › Article
- 2009
-
Mark
Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor alpha Therapies Does the Risk Change With the Time Since Start of Treatment?
(
- Contribution to journal › Article